Genotype-Aligned Cannabinoid Formulations for Personalized Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid formulations lack personalization based on individual genetic profiles, leading to inconsistent and unpredictable responses due to varying sensitivities to cannabinoids and terpenes.
Innovation Solution
Developing cannabinoid formulations that align with an individual's genotype by using specific phytocannabinoid ratios and terpene profiles, including CBD:THC ratios and combinations with terpenes like myrcene, linalool, pinene, and beta-caryophyllene, to provide tailored therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If standard cannabinoid formulations are used without genetic personalization, then manufacturing and distribution are simplified, but treatment efficacy and predictability deteriorate
Solution Approach 1:
The patent applies parameter changes by adjusting cannabinoid ratios (CBD:THC) and terpene profiles based on genetic markers. Different formulations are created with specific parameter combinations (e.g., high CBD:low THC for anxiety, low CBD:high THC for pain) that correspond to different genetic profiles, thereby optimizing treatment efficacy for each patient group while maintaining standardized manufacturing processes.
2Reliability
If cannabinoid formulations are personalized based on genetic profiles, then treatment efficacy and predictability improve, but formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent segments the cannabinoid formulation market into distinct categories based on genetic profiles and therapeutic indications. Each segment has a defined cannabinoid ratio and terpene profile (e.g., anxiety formulations with high CBD, pain formulations with high THC). This segmentation allows for standardized production within each category while maintaining overall system complexity management through modular formulation design.
3Stability of the object's composition
If fixed cannabinoid ratios are used in all formulations, then manufacturing consistency is maintained, but individual patient response variability increases
Solution Approach 1:
The patent introduces dynamics into formulation composition by making cannabinoid ratios and terpene profiles adjustable based on patient genetic markers. Instead of a single fixed formulation, the system dynamically adapts the composition parameters (CBD:THC ratio, terpene content) to match individual patient profiles, thereby aligning treatment with patient-specific biological characteristics while maintaining manufacturing consistency within each defined formulation category.
Data Source
AI summary
The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.